Quality of life (QoL) and overall survival (OS) in patients (pts) with advanced clear-cell renal cell carcinoma (aRCC) treated with nivolumab (NIVI) vs. everolimus (EVE) in the phase III CheckMate 025 study Meeting Abstract
| Authors: | Cella, D.; Gruenwald, V.; Nathan, P. D.; Doan, J.; Dastani, H.; Taylor, F.; Bennett, B.; DeRosa, M.; Berry, S.; Broglio, K.; Berghorn, E.; Motzer, R. J. |
| Abstract Title: | Quality of life (QoL) and overall survival (OS) in patients (pts) with advanced clear-cell renal cell carcinoma (aRCC) treated with nivolumab (NIVI) vs. everolimus (EVE) in the phase III CheckMate 025 study |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 256s |
| Language: | English |
| ACCESSION: | WOS:000404665407122 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.4549 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4549 -- Source: Wos |
